| 摘要 |
A new nucleic acid has a sequence: (a) comprising 7093, 7307, 7015 or 7229 bp (dna1-dna4, respectively) fully defined in the specification; (b) corresponding to (a), within the scope of the degeneration of the genetic code; (c) that hybridizes with (a) under stringent conditions; or (d) that codes for a polypeptide with a sequence comprising 2013, 2040, 1987 or 2014 amino acids (P1-P4, respectively) fully defined in the specification. Independent claims are also included for: (1) a polypeptide that: (a) is encoded by the nucleic acid above; (b) comprises any of the sequences P1-P4, or their portions; or (c) comprises the kinase domain of the P1-P4 sequences; (2) an antibody against the polypeptide; (3) a vector that contains at least one copy of the new nucleic acid; (4) cell that is transfixed with the new nucleic acid, or with the vector; (5) a test system for identifying effectors of the polypeptide above; where a polypeptide is incubated with a steroid, a steroid analog or a sterol, and the amount of bound steroid, steroid analog or sterol is detected; (6) a test system for identifying inhibitors of the kinase function of the polypeptide; where the polypeptide is brought into contact with the substances that are to be tested, and the kinase activity is determined; and (7) a process for the preparation of a pharmaceutical agent comprising: (a) substances are brought into contact with the test system above; (b) the action of the substances on the test system is measured in comparison to controls; (c) a substance that shows a modulation of the activity of the polypeptide in step (b) is identified; and (d) the substance that is identified in step (c) is mixed with the formulation substances that are commonly used in pharmaceuticals.
|
